Tamoxifen may stem fungal infections
Posted on: Tuesday, 21 July 2009, 18:36 CDT
A drug used to prevent breast cancer shows promise as a killer of life-threatening fungal infections, U.S. researchers say.
Dr. Damian Krysan of the University of Rochester Medical Center and colleagues found tamoxifen kills yeast in mice with Candida infections. The researchers suggest the drug, used to help prevent breast cancer recurrence, may kill fungus cells and stop them from causing disease.
It's still early, but if tamoxifen, or molecules like it, turns out to be an effective treatment against serious fungal infections, it'll be a welcome addition to our arsenal,
Krysan said in a statement.
Fungal infections can be deadly in patients with low immunity, Krysan said, and fungus is the third most common cause of bloodstream infection in premature infants in the neonatal intensive care unit. The survival rate for children with acute lymphoblastic leukemia is about 95 percent, but if they acquire a Candida albicans fungal infection, that drops to 80 percent, the researchers said.
The research findings have been published in Antimicrobial Agents and Chemotherapy.
Source: United Press International
Related Articles
- WPI Researchers Take Aim at Hard-to-Treat Fungal Infections
- Interim Results From a New Trial of CANCIDAS(R) (Caspofungin Acetate) in Pediatric Patients With Documented Fungal Infections
- New Report Examines the Fungal Infections or Candidiasis Drug Pipeline
- FDA Approves Noxafil(R) (Posaconazole) Oral Suspension For Prevention of Life-Threatening Fungal Infections In High-Risk Patients
- European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
- Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients
- Read the Factors That Are Changing the Antifungals Market Today Inside Advances in the Treatment of Serious Systemic Fungal Infections -- An Update
- European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (Posaconazole) Oral Suspension for Treatment of Invasive Fungal Infections
- Mosquitoes Now Pose Fungal Infection Threat
 |
 |
User Comments (0)
RSS Feeds